NASDAQ:MBRX Moleculin Biotech (MBRX) Stock Price, News & Analysis → (Free Workshop) Advanced “bug-out bag” hacks! (From Warrior Life) (Ad) Free MBRX Stock Alerts $4.14 -0.21 (-4.83%) (As of 06/14/2024 08:51 PM ET) Add Compare Share Share Today's Range$3.84▼$4.9050-Day Range$4.14▼$5.2352-Week Range$3.84▼$15.75Volume190,600 shsAverage Volume28,644 shsMarket Capitalization$9.56 millionP/E RatioN/ADividend YieldN/APrice Target$35.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Moleculin Biotech alerts: Email Address Moleculin Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside745.4% Upside$35.00 Price TargetShort InterestHealthy0.95% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($8.79) to ($5.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.46 out of 5 stars 3.5 Analyst's Opinion Consensus RatingMoleculin Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMoleculin Biotech has only been the subject of 2 research reports in the past 90 days.Read more about Moleculin Biotech's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.95% of the float of Moleculin Biotech has been sold short.Short Interest Ratio / Days to CoverMoleculin Biotech has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Moleculin Biotech has recently decreased by 38.30%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMoleculin Biotech does not currently pay a dividend.Dividend GrowthMoleculin Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MBRX. Previous Next 2.0 News and Social Media Coverage News SentimentMoleculin Biotech has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Moleculin Biotech this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Moleculin Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.70% of the stock of Moleculin Biotech is held by insiders.Percentage Held by InstitutionsOnly 15.52% of the stock of Moleculin Biotech is held by institutions.Read more about Moleculin Biotech's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Moleculin Biotech are expected to grow in the coming year, from ($8.79) to ($5.28) per share.Price to Book Value per Share RatioMoleculin Biotech has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Moleculin Biotech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Warrior Life(Free Workshop) Advanced “bug-out bag” hacks!“Do you have a ‘bug-out bag’ (survival kit) ready to grab-and-go when a disaster or other crisis strikes?” Most citizens don’t… but according to my friend (and best-selling survival author), Jeff, even the hardcore “preppers” who cherish their bug-out bags are doing it all wrong!All the details are right here… About Moleculin Biotech Stock (NASDAQ:MBRX)Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.Read More MBRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MBRX Stock News HeadlinesJune 14 at 8:00 AM | prnewswire.comMoleculin Announces Additional Positive Preliminary Interim Data from AML Clinical TrialJune 13, 2024 | americanbankingnews.comStockNews.com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX)June 12, 2024 | prnewswire.comMoleculin to Present at the Virtual Investor Pitch ConferenceJune 5, 2024 | prnewswire.comMoleculin to Participate in the Virtual Investor Lunch Break SeriesMay 16, 2024 | prnewswire.comMoleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid CongressMay 15, 2024 | prnewswire.comMoleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)May 14, 2024 | msn.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comMoleculin Biotech Inc (MBRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...May 13, 2024 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 13, 2024 | prnewswire.comMoleculin Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | investorplace.comMBRX Stock Earnings: Moleculin Biotech Beats EPS for Q1 2024May 10, 2024 | markets.businessinsider.comMoleculin Biotech’s Annamycin Shows Promising Efficacy in AML Treatment, Backed by Strong Clinical Results and Buy RatingMay 9, 2024 | prnewswire.comMoleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for AnnamycinMay 8, 2024 | prnewswire.comMoleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and WebcastMay 7, 2024 | prnewswire.comMoleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject DataMay 2, 2024 | prnewswire.comMoleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024May 1, 2024 | prnewswire.comMoleculin Announces Formation of Scientific Advisory Board to Support Development of AnnamycinApril 26, 2024 | finanznachrichten.deJTC Team, LLC: Moleculin Biotech Participates in Virtual Investor "What This Means" Segment Hosted by JTC TeamApril 18, 2024 | markets.businessinsider.comMoleculin Biotech Says EMA Grants Orphan Drug Designation To Annamycin To Treat AMLApril 18, 2024 | prnewswire.comEuropean Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)April 12, 2024 | investing.comMoleculin Biotech Inc (MBRX)April 10, 2024 | markets.businessinsider.comMoleculin Biotech Reveals Positive Anti-cancer Data For Annamycin With Non-cardiotoxic EffectsApril 10, 2024 | prnewswire.comMoleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic PropertiesMarch 28, 2024 | finance.yahoo.comMoleculin to Present at the MedInvest Biotech & Pharma Investor ConferenceMarch 27, 2024 | finance.yahoo.comMoleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AMLSee More Headlines Receive MBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today6/17/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MBRX CUSIPN/A CIK1659617 Webwww.moleculin.com Phone(713) 300-5160FaxN/AEmployees18Year FoundedN/APrice Target and Rating Average Stock Price Target$35.00 High Stock Price Target$45.00 Low Stock Price Target$20.00 Potential Upside/Downside+745.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,770,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-87.19% Return on Assets-68.91% Debt Debt-to-Equity RatioN/A Current Ratio3.51 Quick Ratio3.51 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.70 per share Price / Book0.35Miscellaneous Outstanding Shares2,310,000Free Float2,157,000Market Cap$9.56 million OptionableNot Optionable Beta1.87 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Walter V. Klemp (Age 64)Founder, Chairman, President & CEO Comp: $894.54kMr. Jonathan P. Foster CPA (Age 60)Executive VP & CFO Comp: $611.17kDr. Donald H. Picker Ph.D. (Age 78)Chief Scientific Officer Comp: $486.44kDr. Waldemar Priebe Ph.D.Co-Founder, Founding Scientist & Chairman of Scientific Advisory BoardDr. John Paul Waymack M.D. (Age 72)Sc.D., Senior Chief Medical Officer Dr. Sandra L. Silberman M.D. (Age 69)Ph.D., Chief Medical Officer of New Products Dr. Wolfram C. M. Dempke M.B.A.M.D., Ph.D., European Chief Medical OfficerMs. Jacqueline Northcut (Age 62)Consultant Comp: $51.11kMr. Louis Ploth Jr. (Age 70)Independent Advisor Comp: $118.49kMore ExecutivesKey CompetitorsVaccinexNASDAQ:VCNXLexaria BioscienceNASDAQ:LEXXFortress BiotechNASDAQ:FBIONanoViricidesNYSE:NNVCEyenoviaNASDAQ:EYENView All CompetitorsInsidersWalter V KlempBought 12,560 shares on 12/26/2023Total: $129,996.00 ($10.35/share)Jonathan P FosterBought 1,932 shares on 12/26/2023Total: $19,996.20 ($10.35/share)Robert E GeorgeBought 966 shares on 12/26/2023Total: $9,998.10 ($10.35/share)View All Insider Transactions MBRX Stock Analysis - Frequently Asked Questions Should I buy or sell Moleculin Biotech stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MBRX shares. View MBRX analyst ratings or view top-rated stocks. What is Moleculin Biotech's stock price target for 2024? 3 Wall Street research analysts have issued twelve-month price objectives for Moleculin Biotech's stock. Their MBRX share price targets range from $20.00 to $45.00. On average, they anticipate the company's stock price to reach $35.00 in the next twelve months. This suggests a possible upside of 745.4% from the stock's current price. View analysts price targets for MBRX or view top-rated stocks among Wall Street analysts. How have MBRX shares performed in 2024? Moleculin Biotech's stock was trading at $12.8760 at the beginning of the year. Since then, MBRX stock has decreased by 67.8% and is now trading at $4.14. View the best growth stocks for 2024 here. Are investors shorting Moleculin Biotech? Moleculin Biotech saw a drop in short interest in the month of May. As of May 31st, there was short interest totaling 21,100 shares, a drop of 38.3% from the May 15th total of 34,200 shares. Based on an average trading volume of 40,200 shares, the days-to-cover ratio is currently 0.5 days. Currently, 1.0% of the shares of the company are short sold. View Moleculin Biotech's Short Interest. When is Moleculin Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our MBRX earnings forecast. How were Moleculin Biotech's earnings last quarter? Moleculin Biotech, Inc. (NASDAQ:MBRX) posted its earnings results on Friday, May, 10th. The company reported ($2.02) earnings per share for the quarter, topping the consensus estimate of ($3.59) by $1.57. When did Moleculin Biotech's stock split? Moleculin Biotech's stock reverse split before market open on Friday, March 22nd 2024. The 1-15 reverse split was announced on Friday, March 22nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Moleculin Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX), Dynavax Technologies (DVAX), OPKO Health (OPK), SCYNEXIS (SCYX) and Exelixis (EXEL). How do I buy shares of Moleculin Biotech? Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MBRX) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored(Free Workshop) Advanced “bug-out bag” hacks!“Do you have a ‘bug-out bag’ (survival kit) ready to grab-and-go when a disaster or other crisis strikes?” ...Warrior Life | SponsoredThe Scary Fed Idea To Turn Your Dollars Into a Digital Power GrabCash is becoming a relic of the past… Soon, Biden and the Federal Reserve plan to replace the dollar with t...Oasis Gold | Sponsored"Trump Loophole" Beats InflationThe demise of the "petrodollar" appears imminent. And the implications for Americans could be dire.Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.